Enhertu followed by THP before surgery showed statistically significant and clinically meaningful improvement in pCR in ...
Positive high-level results from the DESTINY-Breast11 phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in …